The Use of Harpagophytum Procumbens (Martynia Fragrans) in Rheumatology: a Look through the Prism of Comorbidity (Literature Review)
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
The objective: is to highlight the scientific achievements of the use of Harpagophytum procumbens in patients with osteoarthritis and other rheumatic diseases, including the aspect of comorbid processes inherent in this pathology.
Materials and methods. The authors conducted a research in printed and electronic publications, science research bases, the State Register of Medicinal Products of Ukraine using methods of analysis, comparison and synthesis of information data, as well as the results of their own initial studies of the efficacy of Harpagophytum procumbens in patients with osteoarthritis with phenomena comorbid processes.
Results. Materials of scientific researches carried out in different countries of the world testify that the extract of Martynia Fragrans has a multifaceted therapeutic effect of patients with osteoarthritis and age-old comorbid processes due to the properties of this plant like hypotensive, cardiotonic, disaggregant, hypoglycemic, choleretic, which improves the digestive system and kidneys qualities. The indicated properties of drugs with Martynia Fragrans are important in terms of a possible beneficial effect on comorbid diseases of the cardiovascular, digestive, genitourinary systems and diabetes mellitus, which occur in patients with osteoarthritis. A further prospect of clinical research in this direction is presented, which will be in line with the main principles of the «Strategy of the World Health Organization in the field of traditional medicine for 2014–2023».
Conclusions. Preparations of Martynia (Harpagophytum procumbens) root have a multifaceted mechanism of action and are effective and safe in the treatment of patients with osteoarthritis, arthritis, mild and moderate pains. Achievements of traditional medicine and the latest studies of the effects of the extracts of Martynia Fragrans on metabolism, other organs and systems provide prospects for their positive impact on comorbid diseases in osteoarthritis and improve the overall results of treatment of such patients, being the prospects for further research.##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Волошина Л.О. Остеоартроз, полі- і коморбідність: вікові, гендерні, прогностичні і лікувально-профілактичні аспекти: дані трирічного проспективного дослідження /Л.О. Волошина, С.І. Сміян // Укр. ревматол. журн. – 2016. – № 4. – С. 51–57.
Коваленко В.М. Коморбідність і шляхи раціональної фармакотерапії в ревматології //Укр. ревматол. журн. – 2014. – № 2. – С. 12–13.
Савустьяненко А.В. Эффективность экстаркта мартини душистой (сустамар) при остеоартритах, поясничной боли и фибромиалгии: обзор литературы. // Боль. Суставы. Позвоночник. – 2014. – Т. 3, № 13. – С. 45–53. http://www.mif-ua.com/archive/article/39271.
Стратегія Всесвітньої організації охорони здоров’я в галузі народної медицини на 2014–2023 рр. – Женева, Гонконг, 2013. – С. 80.
Anauate M.C., Torres L.M., de Mello S.B. Effect of isolated fractions of Harpagophytum procumbens D.C. (devil’s claw) on COX-1, COX-2 activity and nitric oxide production on whole-blood assay / Phytother. Res. – 2010. – V. 24, № 9. – P. 1365–1369.
Baumler S., Heilpflanzen Praxis Heute. – Urban@Fisher, Munchen. – 2007. – S. 410–412.
Brien S., Levith G.T., McGregor G. Devil’s Claw (Harpagophytum procumbens) as a treatment of osteoarthritis: a review of efficacy and safety. – J. Altern Complement. Med. 2006; 12:981–993.
Bruyere O., Honvo G., Veronese N. et al. An updated algoritm recommendation for the management of knee osteoarthritis from European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculo-sceletal Diseases (ESCEO) / Semin. Arthritis Rheum. 2019 Dec; 49(3): 337–350. doi: 10.1016/J.semarthrit.2019.04.0.08. Epub2019Apr 30.
Chantre P., Cappelaere A., Leblan D. et al. Efficacy and tolerance of Harpagophytum procumbens versus diacerhein in treatment of osteoarthritis // Phytomedicine. – 2000. – V. 7, № 3. – P. 177–183.
Chrubasik S., Künzel O., Thanner J. et al. A 1-year follow-up after a pilot study with Doloteffin for low back pain // Phytomedicine. – 2005. – V. 12, № 1–2. – P. 1–9.
Chrubasik S., Model A., Black A., Pollak S. A randomized double-blind pilot study comparing Doloteffin and Vioxx in the treatment of low back pain // Rheumatology (Oxford). – 2003. – V. 42, № 1. – P. 141–148.
Chrubasik S., Thanner J., Künzel O. et al. Comparison of outcome measures during treatment with the proprietary Harpagophytum extract doloteffin in patients with pain in the lower back, knee or hip // Phytomedicine. – 2002. – V. 9, № 3. – P. 181–94.
Community herbal monograph on Harpagophytum procumbens DC and/or Harpagophytum zeyheri Decne, radix // European Medicines Agency. – 2008. – Doc. Ref.: EMEA/HMPC/251323/2006
Denner S.S. A review of the efficacy and safety of devil’s claw for pain associated with degenerative musculoskeletal diseases, rheumatoid, and osteoarthritis // Holist Nurs. Pract. – 2007. – V. 21. – P. 203–207.
Dugas A.J.Jr., Castaneda A.J., Bonin G.C. et al. Evaluation of the total peroxyl radical-scavenging capacity of flavonoids: structure-activity relationships // J. Nat. Prod. – 2000. – V. 63. – P. 327–331.
Fiebich B., Munos E., Rose T., Weiss G., McGregor G. Molecular Targets of the Antiinflammatory Harpagophytum procumbens (Devil’s claw): Inhibition of TNFα and COX-2 Gene Expression by Preventing Activation of AP-1. Phytother. Res. 2011;26:806-811.doi: 10.1002/ptr.3636.
Gagnier G.G., Chrubasik S., Manheimer E. Harpagophytum procumbens for osteoarthritis and low back pain: A systematic review. – BMC Complementary and Alternat. Med. 2004, 4:13. doi: 10/1186/1472-6852-4-13.
Göbel H., Heinze A., Ingwersen M. et al. Effects of Harpagophytum procumbens LI 174 (devil’s claw) on sensory, motor und vascular muscle reagibility in the treatment of unspecific back pain // Schmerz. – 2001. – V. 15, № 1. – P. 10–18.
Grant L., McBean D.E., Fyfe L., Warnock A.M. A review of the biological and potential therapeutic actions of Harpagophytum procumbens // Phytother. Res. – 2007. – V. 21. – P. 199–209.
Harpagophytum procumbens (Devil’s Claw) // Alternative Medicine Review. – 2008. – V. 13, № 3. – P. 248–252.
Haseeb A., Ansari M.Y., Haggi T.M. Harpagoside Supresses IL-6 Expression in Primary Human Osteoarthritis Chondrocites. G.Orthopaedic Res. 2017, Feb.35:P.311–320. doi: 10.1002/jor.23262.
Hochberg M.C., Altman R.D., April K.T. et al. American College on Rheumatology 2012 recommendation fort he use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip and knee//Arthritis Care Res. (Hoboken). – 2012. – Vol. 64, № 4. – Р. 465–474.
Hostanska K., Melzer J., Rostock M., Suter A., Saller R. Alternation of anti-inflammatory activity of Harpagophytum procumbens (devil’s claw) extract after external metabolic activation with S9 mix / J. Pharm. Pharmacol. 2014;66:1606–1614. doi: 10.1111/jphp.12242.
Huang T.H., Tran V.H., Duke R.K. et al. Harpagoside suppresses lipopolysaccharide- induced iNOS and COX-2 expression through inhibition of NF-kappa B activation // J. Ethnopharmacol. – 2006. – V. 104, № 1–2. – P. 149–155.
Inaba K., Murata K., Naruto S., Matsuda H. Inhibitory effects of devil’s claw (secondary root of Harpagophytum procumbens) extract and harpagoside on cytokine production in mouse macrophages // J. Nat. Med. – 2010. – 64, № 2. – P. 219–222.
Jang M.H., Lim S., Han S.M. et al. Harpagophytum procumbens suppresses lipopolysaccharide-stimulated expressions of cyclooxygenase-2 and inducible nitric oxide synthase in fibroblast cell line L929 // J. Pharmacol. Sci. – 2003. – V. 93, № 3. – P. 367–371.
Kemper K.J. Devil’s Claw (Harpagophytum procumbens) // The Longwood Herbal Task Force and The Center for Holistic Pediatric Education and Research. – 1999.
Kloppenburg M., Kroon F.P., Blanco F.J. et al. 2018 update of the EULAR recommendations for the management of hand osteoarthritis//Ann. Rheum. Dis. 2019 Jan; 78(1):16–24. doi: 10.1136/annrheumdis-2018-213826. Epub 2018 Aug 28.
Loizou S., Lekakis I., Chrousos G.P., Moutsatsou P. Beta-sitosterol exhibits anti-inflammatory activity in human aortic endothelial cells // Mol. Nutr. Food Res. – 2010. – V. 54. – P. 551–558.
Malemud C.J. Biologic basis of osteoarthritis: state oft he evidence. Curr. Opinion Pheumatol. 2015; 27:289–294.
Manon L., Beatrice B., Thierry O., Jocelyne P., Fathi M., Evelyne O., Alain B. Antimutagenic potential of harpagoside and Harpagophytum procumbens against 1-nitropyrene. Pharmacogn. Mag. 2015;11:29. doi: 10.4103/0973-1296.157675.
Mncwangi N., Chen W., Vermaak I., Gericke N. Devil’s Claw – A review of the ethnobotany, phytochemistry and biological activity of Harpagophytum procumbens. J. Ethnopharmacol. 2012;143:755–771. doi:10.1016/j.jep.2012.08.013.
Sanders M., Grundmann O. The use of glucosamine, devil’s claw (Harpagophytum procumbens) and acupuncture as complementary and alternative treatments for osteoarthritis // Altern. Med. Rev. – 2011. – V. 16, № 3. – P. 228–238.
Schaffer L., Peroza L., Boligon A., Athayde M., Alves S., Fachinetto R., Wagner C. Harpagophytum procumbens Prevents Oxidative Stress and Loss of Cell Viability In Vitro. Neurochem. Res. 2013;38:2256–2267.doi: 10.1007/s11064-013-1133-x.
Schulze-Tanzil G., Hansen C., Shakibaei M. Effect of a Harpagophytum procumbens DC extract on matrix metalloproteinases in human chondrocytes in vitro // Arzneimittelforschung. – 2004. – V. 54, № 4. – P. 213–220.
Swain S., Sarmanova A., Coupland C. et al. Comorbidities in Osteoarthritis: A systematic review and metaanalysis of observations // Arthritis Care Res (Hoboken), 2019, Jun 17. doi: 10.1002/acr.24008.
Vlachojannis J., Roufogalis B.D., Chrubasik S. Systematic review on the safety of Harpagophytum preparations for osteoarthritic and low back pain // Phytother. Res. – 2008. – V. 22. – P. 149–152.
Warnock M., McBean D., Suter A. et al. Effectiveness and safety of Devil’s Claw tablets in patients with general rheumatic disorders // Phytother. Res. – 2007. – V. 21, № 12. – P. 1228–
Wegener T., Lüpke N.P. Treatment of patients with arthrosis of hip or knee with an aqueous extract of devil’s claw (Harpagophytum procumbens DC.) // Phytother. Res. – 2003. – V. 17, № 10. – P. 1165–1172.
